Image

SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)

SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. In all MRs taken by patients, the date of imaging and the volume of the tumor are measured, and we aim to establish a natural growth history for non-malignant brain tumors.

Description

Non-malignant central nervous system (CNS) tumor accounts for 70% of all primary CNS tumors, and over 300,000 patients were diagnosed with non-malignant CNS tumor per year in the United States. Not much is known about the natural history of non-malignant CNS tumors, as it is often treated immediately upon detection. However, some of them, especially small and asymptomatic non-malignant CNS tumors should not be treated immediately upon diagnosis but are observed and followed-up by repeated magnetic resonance imaging (MRI). This study aims to make a prospective cohort of non-malignant CNS tumors that do not require immediate treatment and to quantitatively analyze which factors are related to the growth of tumors.

The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had MR re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed neoplasms of CNS WHO grade 2 or lower among primary intracranial tumors and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant.

Eligibility

Inclusion Criteria for retrospective cohort

  • Patients with radiologically diagnosed brain neoplasm of CNS WHO grade 2 or less since 1998
  • Asymptomatic at first visit to the hospital
  • Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit
  • Patients who have had two or more MRs at least 3 months apart
  • No previous radiotherapy or radiosurgery for the brain lesion
  • 18 years old or more

Inclusion Criteria for prospective cohort

  • Patients with newly diagnosed brain neoplasm of CNS WHO grade 2 or less
  • Asymptomatic at first visit to the hospital
  • Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit and who are going to take follow-up MR exams
  • No previous radiotherapy or radiosurgery for the brain lesion
  • 18 years old or more
  • Patients who agree to participate by written consent

Exclusion Criteria

  • Patients who lost follow-up before the second MR exam
  • Patients requiring immediate treatment due to worsening of symptoms within 3 months of the first MR exam
  • Patients suspected to have other than a neoplasm at follow-up MR exams

Study details
    Brain Tumor
    Primary
    Meningioma
    Schwannoma
    Pituitary Adenoma
    Gliomas Benign

NCT05254197

Seoul National University Hospital

28 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.